The current study aimed to determine the effect of intravenous N-acetylcysteine on plasma homocysteine levels when administered during haemodialysis in patients with end-stage renal failure.

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following FDA approval of a new dosing regimen for its liver drug, Acetadote.